BCL2 and cancer: Preclinical results utilising cancer cell lines and mouse models have demonstrated that sonrotoclax is effective against both wild‐type Bcl‐2 and Bcl‐2 G101V, suggesting its potential to overcome venetoclax resistance associated with this mutation.